Minireview: Human Ovarian Cancer: Biology, current management, and paths to personalizing therapy

Endocrinology

Volumn 153, Issue 4, 2012, Pages 1593-1602

  Romero, Ignacio ^a   Bast, Robert C ^b  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; DNA; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; GEMCITABINE; IMATINIB; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NINTEDANIB; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN; SORAFENIB; SUNITINIB; TOPOTECAN; TREBANANIB; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMPUTER MODEL; CYTOREDUCTIVE SURGERY; DRUG SENSITIVITY; DRUG TARGETING; ENDOMETRIOID CARCINOMA; ENZYME ACTIVATION; GENE FUNCTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MUCINOUS CARCINOMA; NONHUMAN; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT SURVEY; TREATMENT DURATION; TUMOR VASCULARIZATION; WILD TYPE;

EID: 84859378520     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-2123     Document Type: Short Survey

References (92)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D 2011 Global cancer statistics. CA Cancer J Clin 61:69-90
2. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR 2006 Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 107:1075-1085
3. Cheng W, Liu J, Yoshida H, Rosen D, Naora H 2005 Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11:531-537 (Pubitemid 40685976)
4. Soslow RA 2008 Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 27:161-174 (Pubitemid 351450675)
5. Silverberg SG 2000 Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7-15 (Pubitemid 30010638)
6. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J 2010 Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 5:e10358
7. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP 2007 A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26-35 (Pubitemid 46092026)
8. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH 2001 Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451-456 (Pubitemid 33069670)
9. Stuart GC, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J, Marth C, Thigpen T, Trimble E 2011 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750-755
10. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS 2010 Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953
11. Landen Jr CN, Birrer MJ, Sood AK 2008 Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26:995-1005 (Pubitemid 351398093)
12. Shih IeM, Kurman RJ 2004 Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518 (Pubitemid 38529752)
13. Bast Jr RC, Hennessy B, Mills GB 2009 The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428
14. Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR 2011 Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719-725
15. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG 2004 Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496-504 (Pubitemid 38436523)
16. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM 2004 Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10:6432-6436 (Pubitemid 39346537)
17. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM 2008 Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108:510-514
18. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ 2009 Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114:48-52
19. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, Gore ME 2004 Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22:1040-1044 (Pubitemid 41095036)
20. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N 2002 Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281-287
21. Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC 2002 Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 20:11-23 (Pubitemid 34151056)
22. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC 2001 k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 20:244-251
23. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ 2005 Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422-6430 (Pubitemid 41338978)
24. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz Jr LA, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N 2010 Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228-231
25. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, et al. 2010 ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532-1543
26. Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer Statistics 2009. CA Cancer J Clin 59:225-249
28. Giede KC, Kieser K, Dodge J, Rosen B 2005 Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 99:447-461 (Pubitemid 41502860)
29. Colombo N, Pecorelli S 2003 What have we learned from ICON1 and ACTION? Int J Gynecol Cancer 13(Suppl 2):140-143 (Pubitemid 38228755)
30. Odicino F, Pecorelli S, Zigliani L, Creasman WT 2008 History of the FIGO cancer staging system. Int J Gynaecol Obstet 101:205-210
31. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A 2009 Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16:1324-1330
32. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR 2006 Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933-1939 (Pubitemid 43673208)
33. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J 2001 Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007 (Pubitemid 32176274)
34. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B 1996 Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955 (Pubitemid 26428219)
35. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gyncologic Oncology Group 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43
36. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K 2009 Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338
37. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM 2009 Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425
38. González-Martín AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A, Cervantes A 2005 Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16:749-755 (Pubitemid 40767095)
39. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C 2003 Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
40. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E 2006 Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707 (Pubitemid 46630933)
41. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A 2010 Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323-3329
42. Bast Jr RC, Markman M 2010 A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol 7:559-560
43. Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators 2004 Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8
44. Gynecologic Oncology Group; Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S 2006 Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101:436-440
45. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF 1997 Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193 (Pubitemid 27251118)
46. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L 1998 A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9:1343-1345 (Pubitemid 29045575)
47. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171 (Pubitemid 350237599)
48. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186 (Pubitemid 350232248)
49. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA 2004 A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 95:624-631 (Pubitemid 39592531)
50. Rose PG, Blessing JA, Mayer AR, Homesley HD 1998 Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16:405-410 (Pubitemid 28135580)
51. Yin BW, Lloyd KO 2001 Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276:27371-27375
52. Bast Jr RC, Spriggs DR 2011 More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol 121:429-430
53. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski Jr VR, Knapp RC 1983 A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887 (Pubitemid 13014028)
54. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM 2010 Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155-1163
55. Bast Jr RC 2010 Commentary: CA125 and the detection of recurrent ovarian cancer: A reasonably accurate biomarker for a difficult disease. Cancer 116:2850-2853
56. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG 1990 A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97:922-929 (Pubitemid 20340625)
57. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, van Nagell Jr JR, Zhang Z 2011 Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 117:1289-1297
58. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ 2010 Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203:228.e1-6
59. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ 2011 Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 118:280-288
60. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I 2009 Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10:327-340
61. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L, Harris S, Adeyinka OW, Fritsche HA, Bast RC 2010 A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol 28:15s (Abstract 5003)
62. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM 2000 Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18:106-115 (Pubitemid 30036343)
63. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6 (Pubitemid 26012496)
64. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W 2003 Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 13:144-148 (Pubitemid 38228756)
65. Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast Jr RC 2011 Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 71:5806-5817
66. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Australian Ovarian Cancer Study Group, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast Jr RC 2010 SIK2 is a centrosome kinase required for bipolar spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18:109-121
67. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC 2003 Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63:1311-1316 (Pubitemid 36348710)
68. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL 2003 Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 9:5299-5305 (Pubitemid 37413583)
69. Agarwal R, Kaye SB 2003 Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3:502-516 (Pubitemid 37328838)
70. Turner N, Tutt A, Ashworth A 2004 Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819 (Pubitemid 39331153)
71. Bast Jr RC, Mills GB 2010 Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28:3545-3548
72. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S 2008 Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26:20-25
73. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME 2008 "BRCAness"syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536
74. Malander S, Rambech E, Kristoffersson U, Halvarsson B, Ridderheim M, Borg A, Nilbert M 2006 The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 101:238-243
75. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA 2006 Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kincohort study in Ontario, Canada. J Natl Cancer Inst 98:1694-1706 (Pubitemid 44942707)
76. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R 2005 BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104:2807-2816 (Pubitemid 41798292)
77. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG 2008 Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8:17
78. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB 2010 Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28:3570-3576
79. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK 2000 The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899-239903
80. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A 2010 Oral poly-(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-251
81. Bast Jr RC, Mills GB 2012 Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discovery 2:16
82. Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL, Degenhardt Y 2011 Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 50:606-618
83. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A 2009 Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1:315-322
84. Folkman J 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
85. Jubb AM, Harris AL 2010 Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
86. Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL 2011 Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr 2011:71-74
87. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D 21 July 2011 Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 10.1002/ijc.26282
88. Richards JS 2012 Animal models and mechanisms of ovarian cancer development. Endocrinology 153:1585-1592
89. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN 2003. Pathology and classification of ovarian tumors. Cancer 97:2631-2642 (Pubitemid 36539064)
90. Knapp RC, Berkowitz RS, Leavitt Jr T, Bast Jr RC 1988 Natural history and detection of ovarian cancer. In: Sciarra JW, ed. Gynecology and obstetrics. Philadelphia: Harper, Row; 1-16
91. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators 2011 A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med: 365(26):2484-96; 2012 Erratum in: N Engl J Med:366(3):284
92. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group 2011 Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med:365(26):2473-83